Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data

Paris, Christophe; Perrin, Sophie; Hamonic, Stéphanie; Bourget, Baptiste; Roué, Clémence; Brassard, Olivier; Tadié, Émilie; Gicquel, Vincent; Bénézit, François; Thibault, Vincent; Garlantézec, Ronan; Tattevin, Pierre

doi:10.1016/j.cmi.2021.06.043

Cited by 54 publications

(49 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirty days after the start of the vaccination campaign, the infection rate of SARS-CoV-2 among HCWs in the two teaching hospitals of Trieste plummeted, confirming a VE reported also by a number of studies [4,5,7,8,[17][18][19][20][21][22][23].…”

Section: Incidence Of Sars-cov-2 Infectionsupporting

confidence: 72%

Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy)

Basso

Negro

Cegolon

et al. 2022

Viruses

View full text Add to dashboard Cite

Background: Healthcare workers (HCWs) are particularly exposed to biological risk, including SARS-CoV-2 infection. In order to contrast the current pandemic and alleviate the burden of the disease on the healthcare system, a mass vaccination campaign against COVID-19 has been launched worldwide. Aim To evaluate the impact of COVID-19 vaccination in HCWs exposed to SARS-CoV-2, to describe the clinical presentation of COVID-19 in infected HCWs, and to investigate clinical and occupational risk factors for breakthrough infection. Design: Retrospective cohort study. Methods: The cohort of HCWs of Trieste Hospitals were followed up from 1 March 2020, to 30 November 2021 (21 months). All HCWs were periodically screened for SARS-CoV-2 infection by real-time PCR (RT–PCR) analysis. Clinical data were obtained through routine medical surveillance records. Risk factors for SARS-CoV-2 infection were investigated by univariable as well as multivariable logistic regression analysis. Results: Among 4394 HCWs routinely screened for SARS-CoV-2 by PCR on nasopharyngeal swab, a total of 800 incident cases were identified during the entire study period (1 March 2020 to 30 November 2021). Five hundred and sixty-four cases occurred before, and 236 after the start of the vaccination campaign against COVID-19, of whom 155 received a complete vaccination scheme before SARS-CoV-2 infection. Breakthrough infection was featured by mild or no symptoms and was significantly associated with the male sex, BMI > 25, and diabetes mellitus. Some categories of HCWs (physicians and nurse aids/auxiliary personnel) were at a higher risk of breakthrough infection. Conclusions: Fully vaccinated HCWs were less likely to acquire symptomatic as well as asymptomatic SARS-CoV-2 infection. Risk factors for SARS-CoV-2 infection after a full COVID-19 vaccination scheme included the male gender, diabetes mellitus, and overweight. HCWs with higher exposure to COVID-19 patients were at higher risk of breakthrough infection.

show abstract

Section: Incidence Of Sars-cov-2 Infectionsupporting

confidence: 72%

Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy)

Basso

Negro

Cegolon

et al. 2022

Viruses

View full text Add to dashboard Cite

show abstract

“…Overall, the responder rate to Covishield was 83% on day 14, 98% on day 28 after the first dose, and 100% on day 14 after the second dose. Our results were similar to other studies after the first dose of ChAdOx1 [8,9].…”

Section: Discussionsupporting

confidence: 93%

Booster and anergic effects of the Covishield vaccine among healthcare workers in South India

Kannian¹,

Mahanathi²,

Veeraraghavan³

et al. 2021

Preprint

View full text Add to dashboard Cite

Covishield (same as ChAdOx1) vaccine was rolled out in January 2021 against SARS-CoV2 in India. Although studies show good efficacy after two doses, there is limited data on the fate of the elicited antibody responses over time in groups with or without prior exposure to SARS-CoV2. Therefore, in this study we proposed to test naïve or previously exposed healthcare workers (HCWs) longitudinally after both doses for anti-SARS-CoV2 spike antibody (ASSA) levels. Serum samples were collected from 205 HCWs at days 14 and 28 after first dose, and at days 14, 28 and 3-months after second dose. ASSA levels were quantitated by ECLIA method. Non-responder rate was 17% (35/205) on day 14 and 2% (5/205) on day 28 after the first dose. After the second dose, the responder rate was 100%. Non-responder rate was significantly higher among males (p<0.00001) and senior citizens (p=0.008). The second dose boosted a 27-fold increase in the COVID-19 naïve (CN) group, but caused a 1.5-fold decline in the previously exposed groups. By three months, the antibody levels declined 3-4-folds in all the groups. In spite of high antibody levels (GM-1007 U/ml) after the second dose, 14% developed mild breakthrough infections (BTI). The booster effect was significantly higher when given 10-14 weeks later. The responder rate for Covishield was 98% after first dose and 100% after second dose. The vaccine elicited a prime-boost effect in CN HCWs and a boost-anergy effect in the previously exposed HCWs. ASSA levels began to decline proportionately by three months.

show abstract

“…Research communities around the world are in the process of developing safe, effective, and affordable vaccines against COVID-19. As of June 3, 2021, the World Health Organization has evaluated and recommended the emergency use of COVID-19 vaccines developed by AstraZeneca/Oxford, Moderna, Johnson and Johnson, Pfizer/BioNTech, Sinopharm, and Sinovac Biotech based on satisfactory published findings on the safety and efficacy profiles of these vaccines [ 19 – 26 , 72 , 73 ]. Although data on immunological characteristics of patients with COVID-19 are limited, growing experimental evidence suggests that B and T cells are naturally activated during infection, and they contribute substantially towards the resolution of SARS-CoV-2 infection [ 16 – 18 , 74 , 75 ].…”

Section: Discussionmentioning

confidence: 99%

Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins

et al. 2021

View full text Add to dashboard Cite

All approved coronavirus disease 2019 (COVID-19) vaccines in current use are safe, effective, and reduce the risk of severe illness. Although data on the immunological presentation of patients with COVID-19 is limited, increasing experimental evidence supports the significant contribution of B and T cells towards the resolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite the availability of several COVID-19 vaccines with high efficacy, more effective vaccines are still needed to protect against the new variants of SARS-CoV-2. Employing a comprehensive immunoinformatic prediction algorithm and leveraging the genetic closeness with SARS-CoV, we have predicted potential immune epitopes in the structural proteins of SARS-CoV-2. The S and N proteins of SARS-CoV-2 and SARS-CoVs are main targets of antibody detection and have motivated us to design four multi-epitope vaccines which were based on our predicted B- and T-cell epitopes of SARS-CoV-2 structural proteins. The cardinal epitopes selected for the vaccine constructs are predicted to possess antigenic, non-allergenic, and cytokine-inducing properties. Additionally, some of the predicted epitopes have been experimentally validated in published papers. Furthermore, we used the C-ImmSim server to predict effective immune responses induced by the epitope-based vaccines. Taken together, the immune epitopes predicted in this study provide a platform for future experimental validations which may facilitate the development of effective vaccine candidates and epitope-based serological diagnostic assays.

show abstract

Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data

Cited by 54 publications

References 7 publications

Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy)

Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy)

Booster and anergic effects of the Covishield vaccine among healthcare workers in South India

Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins

Contact Info

Product

Resources

About